Rare Diseases Drug Development Solutions and Clinical Trials

Combining extensive rare disease clinical trial experience with actionable, patient-centric approaches to address high unmet medical needs

At Covance, we recognize the importance of developing therapies to address indications with high unmet medical needs. About 200 approved therapies exist for just a few of the 7,000+ rare diseases affecting more than 350 million people who live with a rare disease.

file

Achieve success with integrated, patient-centric solutions

Address the inherent complexities of rare disease drug development with combined capabilities and comprehensive solutions across Covance, LabCorp and Chiltern.

Identify & mitigate risks early with proven clinical trial experience

Therapeutic Area

# of Full Service Studies

# of Sites # of Subjects

Bone & Joint Disease

2

45

162

Cardiovascular

14

795

4,109

Dermatology

2

109

304

Endocrinology and Metabolism

19 525 23,780

Gastroenterology and Hepatology

3 169 410

Hematology

6

42

235

Immunology

5

112

702

Infectious Disease

5

128

650

Nephrology

4

187

1,345

Neuroscience

18

354

1,324

Oncology

108

4,187

17,131

Ophthalmology

11

117

892

Pulmonary/Respiratory

31

1,374

4,994

Women's Health

1

20

55

Grand Total

229

8,164

56,093

Align with the evolving paradigm of patient centricity

Forge stronger partnerships with patient groups through:

  • Use of patient input to help inform study design
  • Education and dissemination of clinical study information
  • Enhanced patient identification and participation
  • Capture and incorporation of “voice of the patient”

Receive world-class clinical development services

Access integrated solutions and proven operational capabilities to:

  • Leverage genetic counselor networks and LabCorp “opt-in” patient care data, informing patient-centric approaches to trial designs
  • Obtain regulatory insights to guide in study designs and paths to regulatory approval
  • Recognize the value of service and quality results by employing a single-source provider
  • Access expert genomic and diagnostic solutions

From early stage development to the clinic, from award to completion, you can trust in our established and dedicated Rare Disease Drug Development Team every step of the way. We’ll apply best practices, provide therapeutic area expertise and ongoing consultation and pull-in other experts as needed. The end result is a truly patient-centric approach to rare disease clinical trials that eases the burden on sites and patients.